NASDAQ:GENE - Genetic Technologies Stock Price, Price Target & More

$1.3234 -0.02 (-1.49 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$1.3234

Today's Range$1.30 - $1.35

52-Week Range$0.70 - $2.05

Volume49,989 shs

Average Volume71,302 shs

Market Capitalization$21.49 million

P/E RatioN/A

Dividend YieldN/A

Beta3.37

About Genetic Technologies (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. The company has research and services agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:GENE

CUSIPN/A

Webwww.gtglabs.com

Phone61-3-8412-7000

Debt

Debt-to-Equity RatioN/A

Current Ratio7.02%

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$390,000.00

Price / Sales55.11

Cash FlowN/A

Price / CashN/A

Book Value$0.49 per share

Price / Book2.70

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees20

Outstanding Shares16,240,000

How to Become a New Pot Stock Millionaire

Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are some of Genetic Technologies' key competitors?

Some companies that are related to Genetic Technologies include Pure Bioscience (PURE), IntelGenx Technologies (IGXT), Omnicomm Systems (OMCM), Vaxart (VXRT), Vivus (VVUS), Celsion (CLSN), Presbia (LENS), Proteon Therapeutics (PRTO), ANGLE (AGL), ReNeuron (RNUGF), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), Cellect Biotechnology (APOP), PLx Pharma (PLXP), Chiasma (CHMA), Soleno Therapeutics (SLNO), Edge Therapeutics (EDGE) and Lipocine (LPCN).

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the folowing people:

Dr. Paul Alexander Kasian Ph.D., Chairman & Acting CEO (Age 61)
Mr. Kevin Fischer CPA, AGIA, ACIS, B.Com., CFO & Company Sec.
Dr. Richard Allman Ph.D., Scientific Director (Age 58)
Ms. Diana Newport, Quality & Bus. Operations Director (Age 61)
Ms. Bronwyn M. Christie B.Com., CPA, Grd Dip C.G., Financial Controller

Has Genetic Technologies been receiving favorable news coverage?

News headlines about GENE stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genetic Technologies earned a daily sentiment score of 0.16 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $1.3234.

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $21.49 million and generates $390,000.00 in revenue each year. Genetic Technologies employs 20 workers across the globe.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected].com.

MarketBeat Community Rating for Genetic Technologies (GENE)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		59 (Vote Outperform)
Underperform Votes:		66 (Vote Underperform)
Total Votes:		125

MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Genetic Technologies (NASDAQ:GENE) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 4/22/2016 forward)

Genetic Technologies (NASDAQ:GENE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Genetic Technologies (NASDAQ GENE) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 6.48%

Insider Trading History for Genetic Technologies (NASDAQ:GENE)

Genetic Technologies (NASDAQ GENE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Genetic Technologies (NASDAQ GENE) News Headlines

Source:

Date	Headline
	These former SpaceX engineers are helping scientists find cures for genetic diseases www.cnbc.com - April 20 at 9:22 AM
	Taconic Biosciences Licenses Easi-CRISPR Technology from the University of Nebraska globenewswire.com - April 20 at 9:22 AM
	These ex-SpaceX engineers are helping scientists find cures for genetic diseases uk.finance.yahoo.com - April 19 at 4:50 PM
	Gates backs gene technologies in fight to end malaria www.reuters.com - April 18 at 4:55 PM
	True Health Launches New Genetic Carrier Screening www.bizjournals.com - April 16 at 4:36 PM
	Employees Jump at Genetic Testing. Is That a Good Thing? www.nytimes.com - April 16 at 9:06 AM
	Bill Gates says it would be a 'tragedy' to pass up a controversial, revolutionary gene-editing technology www.msn.com - April 14 at 9:21 AM
	A controversial technology could save us from starvation — if we let it www.businessinsider.com - April 12 at 4:41 PM
	Global Direct-to-Consumer Genetic Health Testing Market Report 2018 globenewswire.com - April 12 at 10:00 AM
	Estonia offers free genetic testing in nationwide experiment abcnews.go.com - April 12 at 10:00 AM
	Belgium Infectious Disease Testing Market 2018-2023 - Current & Emerging Products, Technology Review and Opportunities - ResearchAndMarkets.com www.finanznachrichten.de - April 10 at 4:41 PM
	Can the Gene-Editing Technology CRISPR Cure This Debilitating Brain Disease? www.msn.com - April 10 at 4:41 PM
	Mars Petcare Acquisition of OptiGen, LLC Will Enable Discovery of New Genetic Health Markers for Dogs www.prnewswire.com - April 10 at 4:41 PM
	Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders globenewswire.com - April 10 at 9:37 AM
	Counsyl Highlights Importance of Patient Access to Genetic Testing at the 2018 ACMG Annual Clinical Genetics Meeting www.businesswire.com - April 5 at 9:19 AM
	Study begins to reveal genetic ties behind a neurological phenomenon www.msn.com - March 31 at 4:41 PM
	Laboratory for Advanced Medicine Provides Select Doctors with Revolutionary New IvyGene Technology for Early Cancer Diagnosis and Detection www.bizjournals.com - March 26 at 9:37 AM
	Global Genetic Disorders Partnering 2012-2018: Deal Trends, Players and Financials - ResearchAndMarkets.com www.bizjournals.com - March 24 at 4:35 PM
	Invictus MD Strategies Corp. Opens the Market finance.yahoo.com - March 20 at 4:33 PM
	Genetic Technologies Limited (GENE) Short Interest Update www.americanbankingnews.com - March 14 at 1:38 AM
	Genetic tweak makes plants use 25% less water www.msn.com - March 7 at 9:21 AM
	Genetic Tech to team up with Project Shivom to create large genetic database seekingalpha.com - March 7 at 9:21 AM
	Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysis finance.yahoo.com - March 6 at 4:59 PM
	Genetic Technologies Limited: Project Shivom Strategic Alliance finance.yahoo.com - March 6 at 9:06 AM
	Genetic Technologies Announces Strategic Alliance and Capital Raising finance.yahoo.com - February 23 at 9:09 AM
	Change of Chief Executive Officer finance.yahoo.com - February 6 at 9:17 AM
	Trial by fire: Two Cambridge biotechs race to find a gene therapy cure for Duchenne www.bizjournals.com - February 1 at 4:16 PM
	Results from 31 January 2018 General Meeting finance.yahoo.com - January 31 at 9:39 AM
	BRIEF-Genetic Technologies Seeks Trading Halt www.reuters.com - January 30 at 4:19 PM
	Will Technology In Healthcare Make The Rich Healthier And The Poor Sicker? www.forbes.com - January 30 at 4:19 PM
	Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2017 finance.yahoo.com - January 29 at 9:27 AM
	Genetic Technologies Limited (GENE) Short Interest Up 67.9% in January www.americanbankingnews.com - January 28 at 2:34 AM
	The Market for Direct-to-Consumer Genetic Health Testing, with Key Focus on Quest Diagnostics and LabCorp www.finanznachrichten.de - January 19 at 10:24 AM
	Genetic Technologies Regains Nasdaq Listing Compliance finance.yahoo.com - January 9 at 9:23 AM
	MediSapiens Joins the FinnGen Project and Brings Solutions to Curation, Management and Visualization of Genetic and Clinical Data of 500.000 Finns www.bizjournals.com - December 23 at 8:06 PM
	Global Recombinant DNA (rDNA) Technology Market Report, Size, Share, Analysis 2017 and Forecast to 2023 www.marketwatch.com - October 31 at 8:11 PM
	Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules www.nasdaq.com - October 30 at 7:52 PM
	Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 September 2017 finance.yahoo.com - October 30 at 7:52 PM
	Antibody Drugs: Technologies and Global Markets www.bizjournals.com - October 10 at 4:43 PM
	Today's Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Genetic Technologies finance.yahoo.com - October 5 at 8:34 AM
	A Moral Duty To Abort www.huffingtonpost.com - September 23 at 5:46 AM
	Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus® finance.yahoo.com - September 22 at 2:35 PM
	Global Industrial Enzyme Market Growth Estimated At CAGR Of 5.8% For The Forecast Period 2016-2023: Occams Business Research & Consulting Pvt. Ltd. www.thestreet.com - September 13 at 5:51 AM
	Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended June 30, 2017 : September 1, 2017 finance.yahoo.com - September 1 at 7:21 PM
	Benitec Biopharma's (BNIKF) CEO Greg West on Q2 2017 Results - Earnings Call Transcript seekingalpha.com - August 31 at 3:54 AM
	Genetic Technologies Announces Comprehensive Review of Strategic Alternatives finance.yahoo.com - August 25 at 5:47 AM
	Silicon Valley Startup Grail Sees Hope for Cancer Blood Test www.bloomberg.com - August 9 at 7:09 PM
	Inside the Secret World of Global Food Spies www.bloomberg.com - August 7 at 4:17 PM
	Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa globenewswire.com - August 7 at 4:17 PM
	DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar www.rttnews.com - August 5 at 12:18 AM